CF PHARMTECH (02652): Recommended to fully implement H-share circulation.
Changfeng Pharmaceutical (02652) announced that on November 25, 2025, the board of directors of the company considered and approved the establishment...
CF PHARMTECH (02652) announced that on November 25, 2025, the board of directors has considered and approved a proposal to convert 1.07 billion shares of non-listed domestic shares held by 20 shareholders of the company into H shares, representing approximately 26.1% of the total issued share capital of the company as of the date of this announcement. The number of non-listed domestic shares that need to be registered with the China Securities Regulatory Commission for full circulation of H shares.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
